InSilicoTrials’ Post

Eva Pharma & Eli Lilly's ongoing collaboration to provide affordable insulin in Egypt and Africa exemplifies the positive impact of such partnerships. In a first for Lilly, they're supplying their active pharmaceutical ingredient (API) for insulin at a significantly reduced price to Eva Pharma. This will allow Eva Pharma to formulate, fill, and finish insulin vials and cartridges in Africa, making them a trusted manufacturer of these life-saving products. Eva Pharma expects to reach an incredible one million people per year by 2030. This aligns perfectly with Lilly's 30x30 initiative, which aims to improve healthcare access for 30 million people in limited-resource settings annually by 2030.

EVA Pharma and Eli Lilly co-hosted a powerful panel at the #WorldHealthAssembly, emphasizing partnerships to enhance access, affordability, and quality of essential #NCD medications. With the rise of #cardiovasculardiseases, #diabetes, and #cancer, LMICs face significant challenges in providing life-saving treatments. Collaborative efforts among pharmaceutical companies, governments, and global organizations are key to driving innovation and strengthening healthcare systems in LMICs. EVA Pharma and Eli Lilly remain committed to delivering high-quality, affordable insulin in Egypt and across Africa. What steps can we take to ensure everyone has access to the medications they need? #WorldHealthAssembly #GlobalHealth #AccessToMedicine #AfricaCDC #RASLifeScienceSolutions #MarketIntelligence #CompetitiveIntelligence #BusinessDevelopment Detailed News: https://lnkd.in/gDukR9Zp Follow our page for more updates: https://lnkd.in/de5zNWmK

EVA pharma (Egypt) & Eli Lilly and Company co-hosted a powerful panel at the #WorldHealthAssembly highlighting the power of partnerships to accelerate access, affordability, and quality of essential #NCD (non-communicable disease) medications. The rise of NCDs like #cardiovasculardiseases #diabetes & #cancer poses a critical global challenge. Additionally, LMICs (low- and middle-income countries) often face significant hurdles in providing these life-saving medications to their populations. The solution is collaborative efforts! Partnerships between pharmaceutical companies, governments & global organizations can drive innovation in manufacturing, streamline regulations, and strengthen healthcare systems in LMICs. EVA pharma & Eli Lilly and Company are committed in their ongoing collaboration to provide high-quality, affordable insulin to millions in Egypt and across Africa. What steps can we take to ensure everyone has access to the medications they need? #WorldHealthAssembly #GlobalHealth #AccessToMedicine #NCD #AfricaCDC #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #PartnerIdentification #BusinessDevelopment #Licensing Detailed News: https://lnkd.in/gDukR9Zp Follow our page for more industry updates: https://lnkd.in/de5zNWmK

📢 Weekly Top 5 Must-Read News in Market Access Today | 13- 19 January Highlights in Life Sciences! Welcome to 13 - 19 January of our weekly newsletter series, where we bring you the most critical updates in market access, healthcare, and pharmaceuticals! Each week, we’ll highlight the top 5 stories making waves in the industry. Stay informed on these pivotal developments with our weekly insights—and don't miss future issues to keep up with everything happening in health sciences! Explore the full articles through the links below: 1️⃣ Cuba Enhances Early Alzheimer’s Detection through Physician Training: https://lnkd.in/d8svwB2H 2️⃣ Alofisel Withdrawn from EU Market Following Ineffective Crohn’s Treatment: https://lnkd.in/d6NMnwwW 3️⃣ AGENAS Launches National Telemedicine Platform in Rome: https://lnkd.in/dTHC5ge6 4️⃣Boehringer Ingelheim and Sutro Biopharma Scale Up Cell-Free ADC Manufacturing: https://lnkd.in/djvtwQdf 5️⃣New Tool Predicts Heart Disease Risk in Elderly Asians: https://lnkd.in/dzTM_D6c

PanAgora Pharma held its 7th Annual Digital Implementation Summit on Wednesday, November 13, at the Pfizer campus in Cambridge. The event brought together esteemed speakers who explored innovative ways for the life sciences industry to leverage emerging opportunities in digital health and digital measurement. Dr. Joseph DiMasi, Director of Economic Analysis at Tufts Center for the Study of Drug Development, delivered a presentation titled "Assessing the Net Financial Benefits of Employing Digital Endpoints in Clinical Trials." He shared key insights, including: ⚪ Digital endpoint usage has doubled every three years since 2015. ⚪ Over half of digital endpoints support secondary clinical trial outcomes. ⚪ The most common medical conditions utilizing digital endpoints are CNS disorders and diabetes. The Summit also provided attendees and speakers with opportunities to learn, network, and discuss how digital health tools can be effectively placed in the hands of patients, physicians, and caregivers. To obtain a copy of the May/June Impact Report on Digital Endpoints, visit https://lnkd.in/dSYX898E or email csdd@tufts.edu For more information about the Digital Implementation Summit, visit https://lnkd.in/dGDfuE-N #clinicaltrials #digitalendpoints #CNS #Diabetes #digitalhealth #digitalmeasurement #digitalimplementation

PanAgora Pharma held its 7th Annual Digital Implementation Summit on Wednesday, November 13, at the Pfizer campus in Cambridge. The event brought together esteemed speakers who explored innovative ways for the life sciences industry to leverage emerging opportunities in digital health and digital measurement. Dr. Joseph DiMasi, Director of Economic Analysis at Tufts Center for the Study of Drug Development, delivered a presentation titled "Assessing the Net Financial Benefits of Employing Digital Endpoints in Clinical Trials." He shared key insights, including: ⚪ Digital endpoint usage has doubled every three years since 2015. ⚪ Over half of digital endpoints support secondary clinical trial outcomes. ⚪ The most common medical conditions utilizing digital endpoints are CNS disorders and diabetes. The Summit also provided attendees and speakers with opportunities to learn, network, and discuss how digital health tools can be effectively placed in the hands of patients, physicians, and caregivers. To obtain a copy of the May/June Impact Report on Digital Endpoints, visit https://lnkd.in/eydqcvQ or email csdd@tufts.edu For more information about the Digital Implementation Summit, visit https://lnkd.in/eAf_XJwT #clinicaltrials #digitalendpoints #CNS #Diabetes #digitalhealth #digitalmeasurement #digitalimplementation

IGC Pharma Q2 FY2025: Advancing #Alzheimer’s #Research & Delivering Results   We’re proud to report significant progress this quarter as we continue our mission to reshape Alzheimer’s care and expand #innovative #treatment options.   Highlights:   Promising Results in Alzheimer’s Research: #Preclinical findings for IGC-AD1 show notable effects on #taupathology, with potential to modify the #disease and address symptoms. Pipeline Progress: IGC-AD1 advances toward #clinicaltrials, while new insights from #AImodeling strengthen our position in Alzheimer’s and GLP-1 agonist research. #FinancialGrowth: A 42% #revenue increase driven by U.S. projects, alongside a 25% decrease in SG&A expenses. Our team’s dedication is transforming #healthcare solutions for the future. Thank you to everyone supporting our journey! Read full article here: https://lnkd.in/e3WjAt_Z #AlzheimersResearch #IGCPharma #HealthcareInnovation

𝐖𝐞 𝐚𝐫𝐞 𝐩𝐥𝐞𝐚𝐬𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐞 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐚 𝐧𝐞𝐰 𝐬𝐭𝐮𝐝𝐲 𝐢𝐧 𝐶𝑙𝑖𝑛𝑖𝑐𝑜𝐸𝑐𝑜𝑛𝑜𝑚𝑖𝑐𝑠 𝑎𝑛𝑑 𝑂𝑢𝑡𝑐𝑜𝑚𝑒𝑠 𝑅𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝐨𝐧 𝐭𝐡𝐞 𝐞𝐜𝐨𝐧𝐨𝐦𝐢𝐜 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐨𝐧𝐜𝐞-𝐰𝐞𝐞𝐤𝐥𝐲 𝐢𝐧𝐬𝐮𝐥𝐢𝐧 𝐢𝐜𝐨𝐝𝐞𝐜 𝐢𝐧 𝐈𝐭𝐚𝐥𝐲. This study explores the pharmacoeconomic impact and quality-of-life benefits of icodec, an innovative basal insulin with weekly administration. By reducing injection frequency from 365 to 52 times per year, icodec not only improves treatment adherence and patient satisfaction but also optimizes costs for the National Health Service (NHS). Key findings include: •𝐂𝐨𝐬𝐭 𝐒𝐚𝐯𝐢𝐧𝐠𝐬: Thanks to a reduction in needle consumption and improved adherence, icodec generates an annual economic benefit of approximately €105.95 per patient. •𝐂𝐨𝐬𝐭-𝐄𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞𝐧𝐞𝐬𝐬: With an incremental utility in terms of Quality-Adjusted Life Years (QALYs), icodec proves to be a cost-effective alternative, showing a dominant Incremental Cost-Effectiveness Ratio (ICER) over daily insulin degludec. •𝐄𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭𝐚𝐥 𝐈𝐦𝐩𝐚𝐜𝐭: The reduced injection frequency also contributes to sustainability, decreasing CO2 emissions by approximately 62% per patient annually. This analysis demonstrates that icodec offers a valuable economic and therapeutic option for diabetes management in Italy, delivering enhanced quality of life without additional costs to the NHS. 🔎 Read the full study to explore these findings (link): https://lnkd.in/dA2f9u8U 𝐀𝐮𝐭𝐨𝐫𝐡𝐬: Enrico Torre, Sergio Di Matteo, Giacomo M. Bruno, Chiara Martinotti, Luigi Carlo Bottaro, Giorgio Lorenzo Colombo #SAVE #HTA #HealthEconomics #Diabetes #Insulin #Adherence #QualityOfLife #Pharmacoeconomics #Sustainability #icodec #novonordisk Novo Nordisk Dove Medical Press DOVE MEDICAL PRESS LIMITED Maria Chiara Valentino Roberta Di Massa Davide Zelioli Emma Lucia Fogliati Alessandro Alfano

Health Technology Assessment Receives R$ 2.9 Million Investment from Brazil’s Ministry of Health for Innovative Research The Brazilian Ministry of Health (Ministério da Saúde,) in partnership with the National Council for Scientific and Technological Development (CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico), is investing R$ 2.9 million in health technology assessment research, focusing on innovative methods and ultra-rare diseases. This initiative, announced at the 5th National Conference on Science, Technology & Innovation, aligns with Brazil's National Science and Technology Strategy for 2024. Health Minister emphasized the integration of health innovations into the Unified Health System as part of a broader R$ 406.2 million investment in health research, aiming to align Brazil’s HTA practices with global best standards. For more details please click the link! https://lnkd.in/dVUc9rcR #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

Earlier this year the Regulatory Science Network Netherlands (RSNN) organised an expert meeting with the title ‘Companion Diagnostics (CDx) – Challenges and Opportunities’. The goal of this RSNN Expert Meeting was to retrieve information from the field in terms of developments, missed topics or technologies, challenges and opportunities related to CDx. The invited experts shared their knowledge, experiences, and personal views in accordance with the Chatham House Rule. The group comprised 18 experts from various backgrounds including academia, industry, governmental bodies and health care professionals (HCPs). The pre-defined questions were: 1. What sort of issues do you foresee to play an important role from a regulatory perspective with respect to CDx in the coming decade? 2. Which technological developments do you expect to pose a challenge or opportunity in the coming decade? a. With respect to emerging IVD technological developments? b. With respect to developments in personalized medicine? 3. CDx play an important role in oncology. Are there other therapeutic fields where CDx may play an important role in the coming decade? 4. What regulatory challenges and opportunities do you foresee in the context of co-development of CDx and the corresponding medicinal product? You can read the meeting report here: https://lnkd.in/dp9TCn8N #IVDR #CDx #companion #diagnostics